Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Liabilities and Shareholders Equity: 2020-2025

Historic Liabilities and Shareholders Equity for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Sep 2025 value amounting to $534.6 million.

  • Tarsus Pharmaceuticals' Liabilities and Shareholders Equity rose 42.06% to $534.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 39.43%. This contributed to the annual value of $377.0 million for FY2024, which is 42.00% up from last year.
  • According to the latest figures from Q3 2025, Tarsus Pharmaceuticals' Liabilities and Shareholders Equity is $534.6 million, which was up 7.99% from $495.0 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' 5-year Liabilities and Shareholders Equity high stood at $534.6 million for Q3 2025, and its period low was $178.9 million during Q4 2021.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $376.3 million (2024), whereas its average is $358.5 million.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Liabilities and Shareholders Equity soared by 106.55% in 2021, and later fell by 25.27% in 2023.
  • Quarterly analysis of 5 years shows Tarsus Pharmaceuticals' Liabilities and Shareholders Equity stood at $178.9 million in 2021, then climbed by 27.36% to $227.9 million in 2022, then climbed by 16.51% to $265.5 million in 2023, then surged by 42.00% to $377.0 million in 2024, then soared by 42.06% to $534.6 million in 2025.
  • Its last three reported values are $534.6 million in Q3 2025, $495.0 million for Q2 2025, and $500.8 million during Q1 2025.